Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease

Journal of Neuroscience

Volumn 21, Issue 22, 2001, Pages 8772-8781

  Martín Aparicio, Ester ^a   Yamamoto, Ai ^b   Hernández, Félix ^a   Hen, René ^b   Avila, Jesús ^a   Lucas, José J ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Absence of cell death; Aggregates; Conditional transgenic mouse model; Fast reversal; Huntington's disease; Proteasome

Indexed keywords

HUNTINGTIN; LACTACYSTIN; PROTEASOME; PROTEASOME INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LOSS; CELL NUCLEUS INCLUSION BODY; CONTROLLED STUDY; CORPUS STRIATUM; GENE EXPRESSION; GENE SILENCING; HUNTINGTON CHOREA; MOUSE; NERVE CELL NECROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; TRANSGENE;

EID: 0035889973     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.21-22-08772.2001     Document Type: Article

References (51)

1. Transgenic mice with an expanded CAG repeat controlled by the human AR promoter show polyglutamine nuclear inclusions and neuronal dysfunction without neuronal cell death
2. Structure and expression of the Huntington's disease gene: Evidence against simple inactivation due to an expanded CAG repeat
3. Impairment of the ubiquitinproteasome system by protein aggregation
4. Evidence for proteasome involvement in polyglutamine disease: Localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro
5. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1
6. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice
7. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation
8. Phosphorylation of a neuronal-specific beta-tubulin isotype
9. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain
10. Development of inhibitory synapses among striatal neurons in vitro
11. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters
12. Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production
13. Trinucleotide instability: A repeating theme in human inherited disorders
14. Nuclear and neuropil aggregates in Huntington's disease: Relationship to neuropathology
15. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity
16. Primary culture of identified neurons from the visual cortex of postnatal rats
17. Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human
18. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release
19. Decreased levels of proteasome activity and proteasome expression in aging spinal cord
20. Possible involvement of proteasome inhibition in aging: Implications for oxidative stress
21. Mutant huntingtin expression in clonal striatal cells: Dissociation of inclusion formation and neuronal survival by caspase inhibition
22. Ataxin-1 nuclear localization and aggregation: Role in polyglutamine-induced disease in SCA1 transgenic mice
23. Huntington aggregates may not predict neuronal death in Huntington's disease
24. Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice
25. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice
26. Calcium, free radicals, and excitotoxic neuronal death in primary cell culture
27. SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein
28. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity
29. Reversing neurodegeneration: A promise unfolds
30. Huntington's disease CAG trinucleotide repeats in pathologically confirmed post-mortem brains
31. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models
32. Genetic neurodegenerative diseases: The human illness and transgenic models
33. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA
34. Intranuclear neuronal inclusions: A common pathogenic mechanism for glutamine-repeat neurodegenerative diseases?
35. Mutational bias provides a model for the evolution of Huntington's disease and predicts a general increase in disease prevalence
36. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions
37. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo
38. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: Implications for Huntington's disease pathology
39. Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein
40. Motoneuronal cell death is not correlated with aggregate formation of androgen receptors containing an elongated polyglutamine tract
41. Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone
42. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
43. Huntington's disease: The challenge for cell biologists
44. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease
45. Developmental regulation of type II calcium/calmodulin-dependent kinase isoforms in rat cerebellum
46. Neuropathological classification of Huntington's disease
47. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation
48. Homozygotes for Huntington's disease
49. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease
50. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease